Research
catalogue.

Retatrutide (often called “Reta”) is an experimental peptide drug candidate studied in clinical trials for obesity and related metabolic conditions. It is not an approved medicine.

Clinical trials have reported substantial weight-loss results while researchers study appetite, energy expenditure, and glucose metabolism. Study results do not establish benefits for this unapproved listing, which is not equivalent to semaglutide or tirzepatide.

Retatrutide (often called “Reta”) is an experimental peptide drug candidate studied in clinical trials for obesity and related metabolic conditions. It is not an approved medicine.

Clinical trials have reported substantial weight-loss results while researchers study appetite, energy expenditure, and glucose metabolism. Study results do not establish benefits for this unapproved listing, which is not equivalent to semaglutide or tirzepatide.

Retatrutide (often called “Reta”) is an experimental peptide drug candidate studied in clinical trials for obesity and related metabolic conditions. It is not an approved medicine.

Clinical trials have reported substantial weight-loss results while researchers study appetite, energy expenditure, and glucose metabolism. Study results do not establish benefits for this unapproved listing, which is not equivalent to semaglutide or tirzepatide.

Retatrutide (often called “Reta”) is an experimental peptide drug candidate studied in clinical trials for obesity and related metabolic conditions. It is not an approved medicine.

Clinical trials have reported substantial weight-loss results while researchers study appetite, energy expenditure, and glucose metabolism. Study results do not establish benefits for this unapproved listing, which is not equivalent to semaglutide or tirzepatide.

Prescription products including Mounjaro and Zepbound are approved for specific indications in some countries and are used under medical supervision. This research-only listing is not a prescription product or substitute for care.

Approved prescription tirzepatide can support blood-sugar control and weight management for indicated patients. Do not assume this listing has the identity, quality, safety, or clinical effects of approved products.

Prescription products including Mounjaro and Zepbound are approved for specific indications in some countries and are used under medical supervision. This research-only listing is not a prescription product or substitute for care.

Approved prescription tirzepatide can support blood-sugar control and weight management for indicated patients. Do not assume this listing has the identity, quality, safety, or clinical effects of approved products.

Research includes skin healing, tissue repair, collagen and elastin production, and skin appearance. It is also used as a topical cosmetic ingredient.

Topical cosmetic use is more established than injectable use. Injectable GHK-Cu remains investigational, and topical evidence should not be assumed to establish injectable safety or efficacy.

Research is exploring MOTS-c’s possible role in insulin sensitivity, glucose metabolism, exercise response, cellular energy regulation, and protection from metabolic stress.

MOTS-c remains experimental and is not an approved human medicine. Human evidence is limited, and marketed longevity or performance claims are not established.

Elamipretide is studied in conditions involving mitochondrial dysfunction, as well as research on muscle performance, heart function, and age-related cellular decline.

Research explores whether targeting the inner mitochondrial membrane may support cellular energy and protect cells from mitochondrial damage. The peptide remains experimental; this is not a general anti-aging or performance treatment.

Glutathione is researched for cellular antioxidant and detoxification systems and for recycling other antioxidants, including vitamins C and E. It is also marketed for skin brightening.

Evidence for significant skin-lightening effects is limited, particularly for systemic or injectable glutathione. Marketing claims do not establish benefit from this listing.

Glutathione is studied in antioxidant and detoxification systems and for recycling antioxidants such as vitamins C and E. It is also marketed for skin brightening.

Evidence that systemic or injectable glutathione significantly lightens skin is limited. Marketing claims do not establish benefit from this listing.

Glutathione is studied in antioxidant and detoxification systems and for recycling antioxidants such as vitamins C and E. It is also marketed for skin brightening.

Evidence that systemic or injectable glutathione significantly lightens skin is limited. Marketing claims do not establish benefit from this listing.

NAD+ and its precursors are actively researched for healthy aging, energy, metabolic health, and cellular function.

Human evidence does not firmly establish that NAD+ supplements or injections reverse aging or dramatically increase energy. Research interest is not proof of benefit from this listing.

KPV is being researched for potential anti-inflammatory effects, particularly in gut- and skin-related pathways.

KPV is experimental and not an approved human medicine. Much of the evidence comes from laboratory and animal studies; claims about treating inflammation, acne, or gut conditions in people should be treated cautiously.

It is marketed as containing riboflavin (vitamin B2), bromelain, and lecithin, although formulation may vary by product and source. This research-only listing is not an invitation to inject.

Claims about fat-dissolving effectiveness and safety should be treated cautiously because regulatory status and clinical evidence vary by country.